You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sanofi/Regeneron’s Libtayo hits the mark in first-line NSCLC

Sanofi and Regeneron have announced positive late-stage results for Libtayo (cemiplimab) plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC) at the 2021 European Society for Medical Oncology (ESMO) virtual congress.